Pluri Inc
PLUR.TA
ILA1 059.00 -3.20%
Exchange: TLV | Sector: Healthcare | Industry: Biotechnology
Q2 2025
Published: Feb 11, 2025

Earnings Highlights

  • Revenue of $0.19M up 76.2% year-over-year
  • EPS of $-0.53 increased by 44.8% from previous year
  • Gross margin of 60.0%
  • Net income of -2.96M
  • "N/A" -
PLUR.TA
Company PLUR.TA

Executive Summary

Pluri Inc reported QQ2 2025 results characterized by a modest top-line and a steep ongoing burn driven by R&D and general and administrative expenses. Revenue for the quarter totaled USD 0.185 million, up 76% year-over-year from the prior-year quarter but down 43% quarter-over-quarter, reflecting seasonality and the company’s early-stage commercialization profile in a capital-intensive development program. Gross profit was USD 0.111 million with a robust gross margin of 60%, signaling some efficiency in cost of revenue despite minimal scale. However, operating losses remained pronounced (EBITDA negative USD 2.831 million; EBIT is negative USD 4.957 million), underscoring the sandbox nature of Pluri’s business model: heavy R&D investment aimed at advancing PLXPAD and related placental-derived therapies rather than near-term revenue generation.

Key Performance Indicators

Revenue
Increasing
185.00K
QoQ: -43.25% | YoY: 76.19%
Gross Profit
Increasing
111.00K
60.00% margin
QoQ: -44.50% | YoY: 102.17%
Operating Income
Increasing
-4.96M
QoQ: 13.05% | YoY: 4.91%
Net Income
Increasing
-2.96M
QoQ: 49.74% | YoY: 39.73%
EPS
Increasing
-0.53
QoQ: 52.68% | YoY: 44.79%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q3 2025 0.43 -0.94 +501.4% View
Q2 2025 0.19 -0.53 +76.2% View
Q1 2025 0.33 -1.12 +503.7% View
Q4 2024 0.10 -1.06 -13.5% View
Q3 2024 0.07 -1.01 -18.4% View